Further supporting the clinical relevance, studies involving high risk melanoma patients demonstrated that HLA-A2-specific p-peptides, such as pIRS21097–1105 and pBCAR3126–134 (YLDpSGIHSGA), induced CD8+ T cell responses 42% and 17% of patients, respectively, in a clinical trial (NCT01846143) involving the pBCAR3 phosphopeptide-tetanus vaccine. This evidence concerns the gene CD8A and melanoma.